India stands at a decisive juncture in the evolution of regenerative medicine. Over the past two decades, the country has developed a strong foundation in stem cell science, supported by academic excellence, clinical diversity, and a growing innovation ecosystem. However, the transition from exploratory research to scalable, evidence-based regenerative medicine remains incomplete. The core issue is not the absence of scientific capability, but the absence of systemic coherence across regulation, translation, manufacturing, and delivery.
Bajpai et al. (Wed,) studied this question.